JP2025515926A - ５－ピリジン－１ｈ－インダゾール系化合物、医薬組成物及び使用 - Google Patents

５－ピリジン－１ｈ－インダゾール系化合物、医薬組成物及び使用 Download PDF

Info

Publication number
JP2025515926A
JP2025515926A JP2024568339A JP2024568339A JP2025515926A JP 2025515926 A JP2025515926 A JP 2025515926A JP 2024568339 A JP2024568339 A JP 2024568339A JP 2024568339 A JP2024568339 A JP 2024568339A JP 2025515926 A JP2025515926 A JP 2025515926A
Authority
JP
Japan
Prior art keywords
group
acid
dmso
calculated
esi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024568339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515926A5 (https=
Inventor
志裕 李
金▲レイ▼ 卞
天星 胡
邁 劉
佳星 宋
志霞 邱
紅茜 呉
熙 徐
▲挙▼波 王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Publication of JP2025515926A publication Critical patent/JP2025515926A/ja
Publication of JP2025515926A5 publication Critical patent/JP2025515926A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024568339A 2022-08-24 2022-11-22 ５－ピリジン－１ｈ－インダゾール系化合物、医薬組成物及び使用 Pending JP2025515926A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202211018173.7A CN115353508B (zh) 2022-08-24 2022-08-24 5-吡啶-1h-吲唑类化合物、药物组合物和应用
CN202211018173.7 2022-08-24
PCT/CN2022/133423 WO2024040768A1 (zh) 2022-08-24 2022-11-22 5-吡啶-1h-吲唑类化合物、药物组合物和应用

Publications (2)

Publication Number Publication Date
JP2025515926A true JP2025515926A (ja) 2025-05-20
JP2025515926A5 JP2025515926A5 (https=) 2025-09-25

Family

ID=84003747

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024568339A Pending JP2025515926A (ja) 2022-08-24 2022-11-22 ５－ピリジン－１ｈ－インダゾール系化合物、医薬組成物及び使用

Country Status (8)

Country Link
US (1) US20260070889A1 (https=)
JP (1) JP2025515926A (https=)
KR (1) KR20250007528A (https=)
CN (1) CN115353508B (https=)
AU (1) AU2022475622A1 (https=)
CA (1) CA3255205A1 (https=)
GB (1) GB2632571A (https=)
WO (1) WO2024040768A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115353508B (zh) * 2022-08-24 2023-07-21 中国药科大学 5-吡啶-1h-吲唑类化合物、药物组合物和应用
CN115785071B (zh) * 2023-01-09 2024-01-26 中国药科大学 3-乙炔基-5-（1h-1,2,3-三唑-4-基）-1h-吲唑类化合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151708A1 (en) * 2012-04-04 2013-10-10 Samumed, Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
JP2014500277A (ja) * 2010-12-09 2014-01-09 アムジエン・インコーポレーテツド Ｐｉｍ阻害剤としての二環式化合物
US20160009682A1 (en) * 2013-03-04 2016-01-14 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2019241540A1 (en) * 2018-06-15 2019-12-19 Samumed, Llc Indazole containing macrocycles and therapeutic uses thereof
WO2022012058A1 (zh) * 2020-07-16 2022-01-20 江苏凯迪恩医药科技有限公司 稠环化合物及其中间体、制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
CN102595899A (zh) * 2009-08-10 2012-07-18 埃皮瑟瑞克斯有限公司 作为wnt/b-联蛋白信号传导途径抑制剂的吲唑及其治疗用途
WO2014134772A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN106032359B (zh) * 2015-03-09 2018-07-20 复旦大学 吲唑类化合物及其制备方法和用途
MX380092B (es) * 2015-11-06 2025-03-11 Samumed Llc Tratamiento de la osteoartritis.
CN105958990B (zh) * 2016-05-24 2019-03-29 内蒙古包钢钢联股份有限公司 光电接近开关保护装置
CA3118093A1 (en) * 2018-09-28 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk1/clk and uses thereof
US20230000842A1 (en) * 2019-01-17 2023-01-05 Samumed, Llc Methods of treating cartilage disorders through inhibition of clk and dyrk
CN115353508B (zh) * 2022-08-24 2023-07-21 中国药科大学 5-吡啶-1h-吲唑类化合物、药物组合物和应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500277A (ja) * 2010-12-09 2014-01-09 アムジエン・インコーポレーテツド Ｐｉｍ阻害剤としての二環式化合物
WO2013151708A1 (en) * 2012-04-04 2013-10-10 Samumed, Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
US20160009682A1 (en) * 2013-03-04 2016-01-14 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2019241540A1 (en) * 2018-06-15 2019-12-19 Samumed, Llc Indazole containing macrocycles and therapeutic uses thereof
WO2022012058A1 (zh) * 2020-07-16 2022-01-20 江苏凯迪恩医药科技有限公司 稠环化合物及其中间体、制备方法和应用

Also Published As

Publication number Publication date
KR20250007528A (ko) 2025-01-14
GB2632571A (en) 2025-02-12
CN115353508A (zh) 2022-11-18
WO2024040768A1 (zh) 2024-02-29
GB202415076D0 (en) 2024-11-27
CN115353508B (zh) 2023-07-21
US20260070889A1 (en) 2026-03-12
CA3255205A1 (en) 2025-03-27
AU2022475622A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
CN102149384B (zh) 作为ep4受体拮抗剂的杂环酰胺衍生物
EP2555768B1 (en) Ire-1 inhibitors
JP4234344B2 (ja) スルホンアミド含有複素環化合物
JP6966423B2 (ja) 縮合環ピリミジンアミノ誘導体、その製造方法、中間体、薬学的組成物及び応用
US20100179137A1 (en) Pyridone compound
EP2460787A1 (en) Amide compounds and their use as PGE2 antagonists.
WO2014023083A1 (zh) PI3Kδ抑制剂
WO2008038768A1 (en) Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the compound
CA2176668C (fr) Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
KR101440015B1 (ko) ｍＰＧＥＳ-1 억제제인 2-아릴인돌 유도체
CN116262736B (zh) 新型氧代吡啶类化合物及其制备方法和用途
JP2025515926A (ja) ５－ピリジン－１ｈ－インダゾール系化合物、医薬組成物及び使用
WO2006008874A1 (ja) アミノチアゾール骨格を有するＣｄｋ４，６選択的阻害剤
MX2013001202A (es) Compuestos de piridina de anillo fusionado.
JP4007743B2 (ja) 血管新生阻害剤
WO2005080392A1 (ja) ピラゾロキノロン誘導体およびその用途
CN115304583B (zh) 靶向抑制clk2的5-吡啶-1h-吲唑类化合物及其应用
JP2002529463A (ja) 化合物
JP6200495B2 (ja) α−置換グリシンアミド誘導体
CA2726666A1 (fr) Derives de 2-oxo-alkyl-1-piperazin-2-one, leur preparation et leur application en therapeutique
JP2025519407A (ja) Ｓａｒｍ１モジュレーター、その調製、及び使用
CN108069954A (zh) 含no供体的喹唑啉酮化合物
EP1541149A1 (en) Phosphodiesterase inhibitor
JP4556371B2 (ja) アシルスルホンアミド誘導体
CN118146197A (zh) 炔类化合物及其制备方法、药物组合物与应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241115

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20241115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260306